Richard C. Young & CO. LTD. Buys 467 Shares of Johnson & Johnson (NYSE:JNJ)

Richard C. Young & CO. LTD. grew its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the fourth quarter, HoldingsChannel reports. The firm owned 74,683 shares of the company’s stock after buying an additional 467 shares during the quarter. Richard C. Young & CO. LTD.’s holdings in Johnson & Johnson were worth $10,801,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of JNJ. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson during the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson in the 3rd quarter worth $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Up 1.3 %

NYSE JNJ opened at $156.18 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $376.02 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The stock has a fifty day moving average of $147.40 and a 200-day moving average of $156.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim boosted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Finally, Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.